Evaluation of Off-Label Recombinant Activated Factor VII for Multiple Indications in Children

Abstract

Despite a paucity of safety and efficacy data, the use of recombinant activated factor VII in children for off-label indications has now surpassed its use in hemophilia. A retrospective chart review was conducted of 46 subjects (age, 6.7 ± 6 years; weight, 26 ± 20 kg) who received recombinant activated factor VII for nonhemophiliac indications between January 1, 2004, and September 1, 2005. Indications for use included prevention (n = 6) or treatment (n = 40) of bleeding due to general surgery, hepatic failure, gastrointestinal bleeding, severe traumatic brain injury, bone marrow transplant, cardiac, acetaminophen overdose, and multiorgan system failure. Decreases in prothrombin time, partial thromboplastin time, and international normalized ratio were observed. No inappropriate thrombotic events were noted. Administration of recombinant activated factor VII was associated with a reduction in coagulation markers without obvious adverse thrombotic events at cost of $4189 per dose. These findings should be confirmed in a prospective trial.

Keywords

NovoSeven Recombinant activated factor VII Bleeding Child.

References

Dodd RY Emerging infections, transfusion safety, and epidemiology. N Engl J Med. 2003;349:1205-1206.

Pealer LN , Marfin AA , Petersen LR , et al; West Nile Transmission Investigation Team. Transmission of West Nile virus through blood transfusion in the United States in 2002. N Engl J Med. 2003;349:1236-1245.

Taylor RW , O'Brien J. , Trottier SJ , et al. Red blood cell transfusions and nosocomial infections in critically ill patients. Crit Care Med. 2006;34:2302-2308.

Hennewig U. , Laws HJ , Eisert S. , Gobel U. Bleeding and surgery in children with Glanzman thrombasthenia with and without the use of recombinant factor VIIa. Klin Padiatr. 2005;217:365-370.

Kalicinski P. , Markiewicz M. , Kaminski A. , et al. Single pre-transplant bolus of recombinant activated factor VII ameliorates influence of risk factors for blood loss during orthotopic liver transplantation. Pediatr Transplant . 2005; 9:299-304.

Chuansumrit A. , Tangnararatchakit K. , Lektakul Y. , et al. The use of recombinant activated factor VII for controlling life-threatening bleeding in Dengue shock syndrome. Blood Coagul Fibrinolysis. 2004;15:335-342.

Brown JB , Emerick KM , Brown DL , Whitington PF , Alonso EM Recombinant factor VIIa improves coagulopathy caused by liver failure. J Pediatr Gastroenterol Nutr. 2003;37:268-272.

Almeida AM , Khair K. , Hann I. , Liesner R. The use of recombinant factor VIIa in children with inherited platelet function disorders. Br J Haematol. 2003;121:477-481.

Tobias JD , Groeper K. , Berkenbosch JW Preliminary experience with the use of recombinant factor VIIa to treat coagulation disturbances in pediatric patients. South Med J. 2003;96:12-16.

10.

Pychynska-Pokorska M. , Moll JJ , Krajewski W. , Jarosik P. The use of recombinant coagulation factor VIIa in uncontrolled postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass. Pediatr Crit Care. 2004; 5:246-250.

11.

Tobias JD , Berkenbosch JW , Russo P. Recombinant factor VIIa to treat bleeding after cardiac surgery in an infant . Pediatr Crit Care Med. 2003;4:49-51.

12.

Egan JR , Lammi A. , Schell DN , Gillis J. , Nunn GR Recombinant activated factor VII in paediatric cardiac surgery. Intensive Care Med. 2004;30:682-685.

13.

Blatt J. , Gold SH , Wiley JM , Monahan PE , Cooper HC , Harvey D. Off-label use of recombinant factor VIIa following bone marrow transplantation . Bone Marrow Transplant. 2001;28:405-407.

14.

Yilmaz BT , Alioglu B. , Ozyurek E. , Akay HT , Mercan S. , Ozbek N. Sucessful use of recombinant factor VIIa (NovoSeven) during cardiac surgery in a pediatric patient with Glanzmann thrombasthenia. Pediatr Cardiol. 2005; 26:843-845.

15.

Veldman A. , Fischer D. , Voigt B. , et al. Life-threatening hemorrhage in neonates: management with recombinant activated factor VII. Intensive Care Med. 2002;28: 1635-1637.

16.

Razon Y. , Erez E. , Vidne B. , et al. Recombinant factor VIIa (NovoSeven) as a hemostatic agent after surgery for congenital heart disease. Paediatr Anaesth. 2005;15:235-240.

17.

Cetin H. , Yalaz M. , Akisu M. , Karapinar DY , Kavakli K. , Kultursay N. The use of recombinant activated factor VII in the treatment of massive pulmonary hemorrhage in a preterm infant, Blood Coagul Fibrinolysis . 2006;17:213-216.

18.

Culic S. Kuljis D. , Armanda V. , Jankovic S. Successful management of bleeding with recombinant factor VIIa (NovoSeven®) in a patient with Burkitt lymphoma and thrombosis of the left femoral and left common iliac veins. Pediatr Blood Cancer. 2006 Mar2; Epub ahead of print.

19.

Tancabelic J. , Haun SE

Management of coagulopathy with recombinant factor VIIa in a neonate with echovirus type 7. Pediatr Blood

Cancer. 2004;43:170-176.

20.

Shander A. , Goodnough LT , Ratko T. , et al. Consensus recommendations for the off-label use of recombinant human factor VIIa (NovoSeven®) therapy. Pharma Ther. 2005;30: 644-658.

21.

Stein DM , Dutton RP , O'Connor J. , et al. Determinants of futility of administration of recombinant factor VIIa in trauma. J Trauma. 2005:59;609-615.

22.

Meng ZH , Wolberg AS , Monroe DM , Hoffman M. The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients . J Trauma. 2003;55: 886-891.